PLANO, Texas, June 27, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) announced today that it plans to release financial and operational results for second quarter 2024 at 7 a.m. Central Time (CT) / 8 a.m. Eastern Time (ET) on Thursday, July 25, 2024. Following the release, Integer management will host a webcast at 8 a.m. CT / 9 a.m. ET to discuss these results. Other forward-looking and material information may also be discussed during this call. Conference call details: Date: Thursday, ...

Core Viewpoint - Integer Holdings Corporation (ITGR) is experiencing growth driven by its research and product development activities, with a strong performance in Q1 2024 contributing to optimism in the MedTech sector, although regulatory challenges and reliance on third-party suppliers pose risks [1][3][17]. Company Performance - Integer Holdings reported robust first-quarter 2024 results, showing year-over-year growth in both top-line and bottom-line metrics, particularly in its Medical segment due to strong product line performance [3][7]. - The company has a market capitalization of $3.93 billion and projects a 12.8% growth rate over the next five years, maintaining strong performance and surpassing Zacks Consensus Estimates in the last four quarters with an average earnings surprise of 10.4% [7][8]. Research and Development - The company is focused on internal technology and capability development to provide differentiated solutions, while also collaborating with external research institutions for unique technology projects [2][8]. - ITGR is enhancing existing products and expanding their applications, particularly in the Cardio & Vascular, Neuromodulation, and Non-Medical Electrochem markets [9][8]. Market Position - Integer Holdings has a solid foothold in the broader MedTech space, particularly in cardiac, neuromodulation, orthopedics, vascular, and advanced surgical markets, serving large multinational original equipment manufacturers [17][1]. - The company is undertaking strategic initiatives to maintain its leadership in the cardiac rhythm management market [9]. Regulatory Environment - The healthcare industry regulations, including the European Medical Device Regulation, impose compliance costs that could affect revenue and operational results [4][10]. - Integer Holdings' product lines are subject to various health and safety regulations at multiple levels, which may lead to higher-than-anticipated costs [10][4]. Estimate Trends - The Zacks Consensus Estimate for Integer Holdings' second-quarter 2024 revenues is projected at $437.3 million, reflecting a 9.3% increase from the previous year [20]. - However, there has been a negative estimate revision trend for 2024, with earnings estimates moving down by 1.3% to $5.27 per share over the past 90 days [5].

PLANO, Texas, June 06, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today announced participation at the 2024 Truist Securities MedTech Conference, to be held June 17 – 18, 2024, in Boston. Integer President and Chief Executive Officer Joseph Dziedzic is scheduled to present as part of a fireside chat on Tuesday, June 18, at 1:55 p.m. ET. A live webcast of the presentation will be accessible un ...

A live webcast of the presentation will be accessible under "News & Events" on the Investor Relations section of the Integer website at investor.integer.net. Integer Holdings Corporation (NYSE:ITGR) is one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, serving the cardiac rhythm management, neuromodulation, and cardio and vascular markets. As a strategic partner of choice to medical device companies and OEMs, the Company is committed to enhancing the ...

Company Overview - Integer Holdings (ITGR) has shown strong momentum in 2023, with shares increasing by 23.6%, outperforming the industry growth of 7.5% and the S&P 500's rise of 10.8% [1] - The company specializes in manufacturing and developing medical devices and components primarily for original equipment manufacturers, operating through two segments: Medical Sales and Non-Medical Sales [2] Growth Catalysts - The upward trend in Integer Holdings' stock price is driven by manufacturing excellence initiatives, an improved supply chain, and a favorable direct labor environment [3] - The company's strong performance in Medical sales and a solid first-quarter 2024 performance are expected to further contribute to growth [3][4] Financial Performance - In the trailing four quarters, sales in Cardiac Rhythm Management (CRM) and Neuromodulation increased by 12% year over year, with the Cardio and Vascular product line sales rising by 18% [5] - Integer Holdings reported a gross profit of $109.8 million in Q1 2024, reflecting a 13.6% year-over-year increase, with gross margin expanding to 26.5% [7] - Adjusted operating profit for the same quarter totaled $47.2 million, a 32.1% increase from the prior year, with adjusted operating margin expanding to 11.4% [7][6] Future Estimates - Earnings per share (EPS) for Integer Holdings are projected to grow by 14.1% and 15.4% in 2024 and 2025, reaching $5.33 and $6.155 respectively [10] - Revenues are expected to rise by 10% and 7.4% in 2024 and 2025, totaling $1.76 billion and $1.89 billion [10]

Core Viewpoint - Integer Holdings Corporation (ITGR) is experiencing growth driven by its research and product development activities, with a strong performance in Q1 2024 and a solid position in the MedTech sector, although it faces challenges from energy market volatility and reliance on third-party suppliers [1][2][10][11]. Group 1: Company Performance - Integer Holdings has a market capitalization of $3.82 billion and projects a 12.8% growth over the next five years, maintaining strong performance [2]. - The company has consistently surpassed the Zacks Consensus Estimate in the last four quarters, achieving an average earnings surprise of 10.4% [2]. - The first-quarter 2024 results showed year-over-year growth in both top-line and bottom-line performance, particularly in the Medical segment [7]. Group 2: Research and Development - The company is focused on developing new products, enhancing existing ones, and expanding their applications [3]. - Integer Holdings collaborates with external research institutions for unique technology projects, complementing its internal development efforts [4]. Group 3: Market Position - Integer Holdings has a stable presence in various MedTech markets, including cardiac, neuromodulation, orthopedics, vascular, and advanced surgical markets, primarily serving large multinational original equipment manufacturers [5]. - The company is actively working to increase market penetration in Cardio & Vascular, Neuromodulation, and Non-Medical Electrochem markets, while maintaining its leadership in cardiac rhythm management [6]. Group 4: Challenges - The company's sales in the energy market are affected by fluctuations in oil and gas prices, which are influenced by political and economic factors [10]. - Integer Holdings relies on a continuous supply of raw materials from third-party suppliers, making it vulnerable to price fluctuations and supply chain issues [11]. Group 5: Estimate Trends - There has been a negative estimate revision trend for 2024, with the Zacks Consensus Estimate for earnings decreasing by 1.8% to $5.34 per share [12]. - The estimated revenue for Q2 2024 is projected at $436.6 million, indicating a 9.1% increase from the same quarter last year [12].

Integer Holdings Corporation (ITGR) delivered adjusted earnings per share (EPS) of $1.14 in the first quarter of 2024, which improved 31% year over year. The figure topped the Zacks Consensus Estimate by 1.8%.The adjustments include expenses related to the amortization of intangible assets and restructuring and restructuring-related charges, among others.GAAP EPS for the quarter was 59 cents, reflecting an improvement of 51.3% year over year.Revenues in DetailInteger Holdings registered revenues of $414.8 m ...

Integer (ITGR) reported $414.81 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 9.5%. EPS of $1.14 for the same period compares to $0.87 a year ago.The reported revenue represents a surprise of +0.37% over the Zacks Consensus Estimate of $413.29 million. With the consensus EPS estimate being $1.12, the EPS surprise was +1.79%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine th ...

Integer (ITGR) came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of $1.12 per share. This compares to earnings of $0.87 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 1.79%. A quarter ago, it was expected that this medical device outsource manufacturer would post earnings of $1.34 per share when it actually produced earnings of $1.39, delivering a surprise of 3.73%.Over the last four qu ...

EXHIBIT 99.1 Integer Holdings Corporation Reports First Quarter 2024 Results ~ Strong start to the year with 1Q24 financial results ~ ~ Reiterate 2024 financial outlook ~ PLANO, Texas, April 25, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) today announced results for the three months ended March 29, 2024. First Quarter 2024 Highlights (compared to First Quarter 2023, except as noted) "Integer started the year strong with first quarter 2024 sales growing 10% versus a year ago and adjuste ...